Country: Canada
Language: English
Source: Health Canada
IBUPROFEN
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
M01AE01
IBUPROFEN
100MG
SUSPENSION
IBUPROFEN 100MG
ORAL
60ML/100ML
OTC
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883005; AHFS:
APPROVED
2004-12-01
_ _ _GlaxoSmithKline Consumer Healthcare ULC. _ _ _ _Page 1 of 56_ PRODUCT MONOGRAPH CHILDREN’S ADVIL CHEWABLE TABLETS Ibuprofen Tablets USP, 50 mg CHILDREN’S ADVIL CHILDREN’S ADVIL FEVER FROM COLDS OR FLU Ibuprofen 100 mg/5 mL Ibuprofen Oral Suspension, USP JUNIOR STRENGTH ADVIL JUNIOR STRENGTH ADVIL FEVER FROM COLDS OR FLU Ibuprofen Tablets USP, 100 mg ADVIL PEDIATRIC DROPS ADVIL PEDIATRIC DROPS FEVER FROM COLDS OR FLU Ibuprofen 40 mg/mL Ibuprofen Oral Suspension, USP Analgesic/Antipyretic GlaxoSmithKline Consumer Healthcare ULC 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Preparation: July 20, 2006 Date of Revision: March 12, 2021 Submission Control No: 244560 _ _ _GlaxoSmithKline Consumer Healthcare ULC _ _ _ _Page 2 of 56_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 4 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 6 ADVERSE REACTIONS .............................................................................................. 13 DRUG INTERACTIONS .............................................................................................. 17 DOSAGE AND ADMINISTRATION ........................................................................... 20 OVERDOSAGE ............................................................................................................ 22 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 24 STORAGE AND STABILITY ...................................................................................... 26 SPECIAL HANDLING INSTRUCTIONS ..................... Read the complete document